SCHEMBL19101944

SCHEMBL19101944

O=C(Nc1cc[nH]n1)c1cc(NC(=O)c2cc([N+](=O)[O-])n[nH]2)n[nH]1

nearest known ligand 0.38

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ DYRK1A Q13627 1/20 0.38
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ CCNA2 P20248 11/20 0.36
▸ CDK2 P24941 11/20 0.36
▸ CCNA1 P78396 11/20 0.36
▸ NPC1 O15118 3/20 0.36
▸ RAB9A P51151 3/20 0.36
▸ MAPT P10636 2/20 0.36
▸ PRKAB2 O43741 1/20 0.34
▸ PRKAG1 P54619 1/20 0.34
▸ PRKAA2 P54646 1/20 0.34
▸ PRKAA1 Q13131 1/20 0.34
▸ PRKAG3 Q9UGI9 1/20 0.34
▸ PRKAG2 Q9UGJ0 1/20 0.34
▸ PRKAB1 Q9Y478 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13387620 0.84 SMN1; SMN2 (0.44) DYRK1AMEN1KMT2ACCNA2CDK2
SCHEMBL13256448 0.82 CCNA2 (0.53) DYRK1AMEN1KMT2ACCNA2CDK2
SCHEMBL13387759 0.78 NQO2 (0.37) DYRK1AMEN1KMT2AMAPT
SCHEMBL1520368 0.76 ALOX15 (0.56) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL1906671 0.75 HDAC3 (0.38) —
SCHEMBL1908029 0.75 ALDH1A1 (0.38) MAPT
SCHEMBL13388282 0.72 MAPK1 (0.41) CCNA2CDK2CCNA1
SCHEMBL4293791 0.70 NPC1 (0.51) MEN1KMT2ANPC1RAB9AMAPT
SCHEMBL627520 0.69 MAPK1 (0.57) NPC1RAB9AMAPT
SCHEMBL4290678 0.69 PLA2G7 (0.46) MEN1KMT2ANPC1RAB9AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9701660-B2 2,6-diaminopyridine compounds suitable for treating diseases associated with amyloid or amyloid-like proteins or for treating or preventing ocular diseases or conditions associated with a pathological abnormality/change in the tissue of the visual system AC IMMUNE S.A. (CH) 2017-07-11 — — US disclosed
Send feedback